Literature DB >> 25694046

Preoperative chemoradiotherapy with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer: long-term results of a phase II trial.

Luying Liu1, Caineng Cao, Yuan Zhu, Dechuan Li, Haiyang Feng, Jialin Luo, Zhongzhu Tang, Peng Liu, Ke Lu, Haixing Ju, Na Zhang.   

Abstract

The aim of this study was to report long-term results of patients with locally advanced rectal cancer treated by neoadjuvant chemoradiotherapy with fluorouracil, leucovorin, and oxaliplatin. From February 2002 to November 2006, a total of 58 patients with locally advanced rectal cancer were recruited. Secondary endpoints included the cumulative incidence of local and distant recurrences, disease-free survival, and overall survival. The median follow-up time was 138 months (109-151 months). The cumulative incidence of local recurrence at 10 years was 12.1%. The cumulative incidence of distant recurrence at 10 years was 53.4%. The overall survival in the intention-to-treat population was 39.5% at 10 years. Disease-free survival in the intention-to-treat population was 41.8% at 10 years. Univariate analysis revealed that pathologic complete response was associated with local recurrence, distant recurrence, disease-free survival, and overall survival (p < .05). Distant recurrence remains the predominant pattern of failure for patients with locally advanced rectal cancer after preoperative chemoradiotherapy and total mesorectal excision. Pathologic complete response is an independent prognostic factor for locally advanced rectal cancer after preoperative chemoradiotherapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25694046     DOI: 10.1007/s12032-015-0512-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  19 in total

1.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

Review 2.  Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.

Authors:  S T Martin; H M Heneghan; D C Winter
Journal:  Br J Surg       Date:  2012-02-23       Impact factor: 6.939

3.  Colorectal cancer statistics, 2014.

Authors:  Rebecca Siegel; Carol Desantis; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-03-17       Impact factor: 508.702

4.  Optimal two-stage designs for phase II clinical trials.

Authors:  R Simon
Journal:  Control Clin Trials       Date:  1989-03

5.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

6.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

7.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

Authors:  Thierry André; Corrado Boni; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Andrea Bonetti; Philip Clingan; John Bridgewater; Fernando Rivera; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

8.  Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

Authors:  Jean-Pierre Gérard; David Azria; Sophie Gourgou-Bourgade; Isabelle Martel-Lafay; Christophe Hennequin; Pierre-Luc Etienne; Véronique Vendrely; Eric François; Guy de La Roche; Olivier Bouché; Xavier Mirabel; Bernard Denis; Laurent Mineur; Jean-François Berdah; Marc-André Mahé; Yves Bécouarn; Olivier Dupuis; Gérard Lledo; Jean-François Seitz; Laurent Bedenne; Béata Juzyna; Thierry Conroy
Journal:  J Clin Oncol       Date:  2012-10-29       Impact factor: 44.544

9.  Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.

Authors:  Yong Sang Hong; Byung-Ho Nam; Kyu-Pyo Kim; Jeong Eun Kim; Seong Joon Park; Young Suk Park; Joon Oh Park; Sun Young Kim; Tae-You Kim; Jee Hyun Kim; Joong Bae Ahn; Seok-Byung Lim; Chang Sik Yu; Jin Cheon Kim; Seong Hyeon Yun; Jong Hoon Kim; Jin-Hong Park; Hee Chul Park; Kyung Hae Jung; Tae Won Kim
Journal:  Lancet Oncol       Date:  2014-09-04       Impact factor: 41.316

10.  Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.

Authors:  Yu Jo Chua; Yolanda Barbachano; David Cunningham; Jacqui R Oates; Gina Brown; Andrew Wotherspoon; Diana Tait; Alison Massey; Niall C Tebbutt; Ian Chau
Journal:  Lancet Oncol       Date:  2010-01-25       Impact factor: 41.316

View more
  3 in total

1.  Addition of oxaliplatin to capecitabine-based preoperative chemoradiotherapy for locally advanced rectal cancer: Long-term outcome of a phase II study.

Authors:  Jianhong Peng; Junzhong Lin; Zhifan Zeng; Xiaojun Wu; Gong Chen; Liren Li; Zhenhai Lu; Peirong Ding; Desen Wan; Zhizhong Pan
Journal:  Oncol Lett       Date:  2017-08-17       Impact factor: 2.967

2.  Total mesorectal excision with or without preoperative chemoradiotherapy for resectable mid/low rectal cancer: a long-term analysis of a prospective, single-center, randomized trial.

Authors:  Fulong Wang; Wenhua Fan; Jianhong Peng; Zhenhai Lu; Zhizhong Pan; Liren Li; Yuanhong Gao; Hui Li; Gong Chen; Xiaojun Wu; Peirong Ding; Zhifan Zeng; Desen Wan
Journal:  Cancer Commun (Lond)       Date:  2018-12-20

3.  Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin.

Authors:  Mohammed Faruk; Sani Ibrahim; Surajo Mohammed Aminu; Ahmed Adamu; Adamu Abdullahi; Aishatu Maude Suleiman; Abdulmumini Hassan Rafindadi; Abdullahi Mohammed; Yawale Iliyasu; John Idoko; Rakiya Saidu; Abdullahi Jibril Randawa; Halimatu Sadiya Musa; Atara Ntekim; Khalid Zahir Shah; Sani Abubakar; Kasimu Umar Adoke; Muhammad Manko; Cheh Agustin Awasum
Journal:  PLoS One       Date:  2021-01-19       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.